Insilico Medicine CEO Alex Zhavoronkov says combining AI with China's R&D ecosystem has shortened drug discovery timelines to about one year. In its fastest case， the company reached a drug candidate in just nine months， compared with a typical cycle of around 13 months. Insilico's first AI-designed drug， Rentosertib， has already entered Phase II trials. But despite the company's large China operation， more than 90% of its revenue still comes from Western pharmaceutical companies. The company now plans to expand its Shanghai R&D center while keeping software sales in China limited. In other words， China remains central to Insilico's research engine， but not yet to its commercial market.
X.PIN@thexpin · XAI 摘要
Insilico Medicine CEO Alex Zhavoronkov称，结合AI与中国研发生态已将药物发现周期缩短至约一年，最快案例仅9个月，而传统周期约13个月。其首款AI设计药物Rentosertib已进入II期临床试验。尽管公司在中国运营规模庞大，超90%收入仍来自西方药企；Insilico计划扩建上海研发中心，但限制在华软件销售，中国目前是其研发引擎核心而非商业市场。
Insilico Medicine CEO Alex Zhavoronkov says combining AI with China's R&D ecosystem has shortened drug discovery timelines to about one year. In its fastest case， the company reached a drug candidate in just nine months， compared with a typical cycle of around 13 months. Insilico's first AI-designed drug， Rentosertib， has already entered Phase II trials. But despite the company's large China operation， more than 90% of its revenue still comes from Western pharmaceutical companies. The company now plans to expand its Shanghai R&D center while keeping software sales in China limited. In other words， China remains central to Insilico's research engine， but not yet to its commercial market.